Catalog No.
DHH02205
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279
Concentration
7.98 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q15116
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
100 mM Pro-Ac, 20 mM Arg, pH 5.0
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ANB-011, TSR-042, CAS: 2022215-59-2
Clone ID
Dostarlimab
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial, PMID: 33001143
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer, PMID: 33251877
Antibodies to watch in 2020, PMID: 31847708
Dostarlimab-gxly, PMID: 34136921
Dostarlimab: First Approval, PMID: 34106455
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design, PMID: 32917522
Dostarlimab, PMID: 34014626
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer, PMID: 32213091
An Integrated Analysis of Dostarlimab Immunogenicity, PMID: 34324079
Dostarlimab for the treatment of endometrium cancer and other solid tumors, PMID: 33729216
Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models, PMID: 34313545
[New drug approval: Dostarlimab - second line in advanced MSI endometrial cancer], PMID: 33994164
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer, PMID: 34427115
18 F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab, PMID: 34441288
Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology, PMID: 34199461
[MSI testing : What is new? What should be considered? German version], PMID: 34043067
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design, PMID: 33682447
For research use only. Not for human or drug use.
